Tiziana Life Sciences Ltd. (TLSA)
Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting
Tiziana is developing foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis patients, with key data expected in 2026. A phase 2 trial of foralumab in early-stage Alzheimer's Disease is set to begin in 2025, targeting microglial activation and neuroinflammation. The global Alzheimer's Disease market is expected to reach $23.8 billion by 2031.
Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center in New York City as part of its ongoing Phase 2 clinical trial of intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Weill Cornell marks the fifth site participating in the trial, joining Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.
Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows
Tiziana Life Sciences Ltd (NASDAQ:TLSA)' investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a 78-year-old patient with moderate Alzheimer's disease (AD), a newly published study has shown. The study, published in the Journal of Clinical Nuclear Medicine, was led by Dr Tarun Singhal and Dr Howard Weiner of Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system.
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer's disease showed a marked reduction in brain inflammation after three months of treatment with its lead drug candidate, intranasal foralumab, under an expanded access program. A PET scan revealed a significant decrease in microglial activation—an indicator of neuroinflammation linked to Alzheimer's progression—according to data presented by Dr Howard Weiner at the 2025 AD/PD Conference in Vienna.
Tiziana shares surge 21% on promising multiple sclerosis data
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares jumped 21% in early trading Tuesday after the company reported positive early-stage data for its experimental multiple sclerosis treatment, nasal foralumab. The open-label study involved 10 patients with non-active secondary progressive MS, a form of the disease where disability progresses despite the absence of relapses and few treatment options exist.
Tiziana reports encouraging results for nasal MS drug in early study
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday that its experimental multiple sclerosis therapy, nasal foralumab, showed positive results in an early-stage study, with patients experiencing stabilised disease progression and reduced signs of brain inflammation. The open-label study followed 10 patients with non-active secondary progressive multiple sclerosis, or na-SPMS, a difficult-to-treat form of the disease in which disability worsens even in the absence of relapses.
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the University of Massachusetts has commenced dosing patients in its ongoing Phase 2 trial of its lead candidate intranasal foralumab, a fully human anti CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis (na-SPMS). UMass joins Brigham and Women's Hospital, Yale Multiple Sclerosis Center, and Johns Hopkins University in actively enrolling and treating trial participants.
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that Johns Hopkins University has begun dosing patients in its Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This marks the third clinical site for the trial, alongside Brigham and Women's Hospital and Yale Medical Center.
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it has begun dosing patients at Yale MS Center in its multicenter Phase 2 trial evaluating intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis (na-SPMS). The study, which aims to assess the safety and effectiveness of foralumab in mitigating disease progression, is also enrolling patients at Johns Hopkins, UMass Medical Center, and Brigham and Women's Hospital, the company said in a statement.
Tiziana submits FDA investigational new drug application
Tiziana Life Sciences Ltd has filed an investigational new drug application with the Food and Drug Administration for a clinical trial in Amyotrophic Lateral Sclerosis (ALS). Tiziana, which is advancing lead candidate intranasal foralumab, said on Tuesday it planned a phase two trial including 20 patients upon clearance.
Tiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study reveals
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a groundbreaking study in Nature Neuroscience that demonstrates promising results for its nasal anti-CD3 therapy in treating traumatic brain injury (TBI). TBI is a leading cause of death and disability worldwide, and current treatments fail to address its long-term effects.
Tiziana Life Sciences nearing completion of long COVID study on foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it expects to complete its preclinical study evaluating its nasal anti-CD3 foralumab as a potential treatment for long COVID in the second quarter of 2025. The company said the study aims to validate foralumab's ability to mitigate persistent brain inflammation, a key driver of the neurological and psychiatric symptoms associated with long COVID.
